Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 5-Day steroid course tame COPD Flare-Ups?

NCT ID NCT02330952

Symptom relief Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at whether taking oral corticosteroids (prednisone) for 5 days can help people with COPD who are having a flare-up. The trial involved 189 adults aged 40 and older who were treated in general practice. Researchers tracked treatment failure, including emergency visits or hospitalizations, over 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Prednisone (a corticosteroid)
What this could lead to
If successful, this could confirm that a short course of oral steroids is an effective and safe treatment for COPD flare-ups in outpatient settings.
What could go wrong
This is a completed Phase 4 trial with 189 participants, so results are available but may not apply to all COPD patients. Corticosteroids have known side effects like increased infection risk and blood sugar changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

189 people

The number who actually took part.

Started

Feb 2015

Finished

May 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 40 years and over * Smoking ≥ 10 pack-years * Patients with suspected acute exacerbation of COPD * Patients who gave their written informed consent to participate in the study Exclusion Criteria: * Known or suspected chronic respiratory disease other than COPD (asthma, bronchiectasis ...) * Suspected pneumonia or pulmonary oedema * Decision of hospitalization * Patients taking oral corticosteroids running or stopped for less than a week before inclusion * Pathology compromising compliance * Fever unexplained by the current AECOPD * Uncontrolled hypertension * Uncontrolled diabetes * Deep infectious disease * History of ancient untreated tuberculosis * Untreated peptic ulcer * Unhealed wound * Ulcerative Colitis * Allergy to steroids * Any severe or uncontrolled infections who are not specified as therapeutic indication in the SPC (Summary of Product Characteristics) * Hepatitis, acute genital herpes, varicella, acute zoster * Live attenuated vaccine, recent or planned * Psychoses not controlled by treatment * Hypersensitivity to prednisone or any of the excipients of Cortancyl®, including lactose intolerance * Patients who have already been included in BECOMEG * Patients who have to move within 8 weeks after inclusion in the study * Patients who are not affiliated to the national health insurance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive (MESH) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease lung disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive (MESH) Pulmonary disease

Contacts and locations

Locations

  • Assistance Publique - Hopitaux Paris

    Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.